icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
KTn7JXfTCNCpzzL2